Log In
BCIQ
Print this Print this
 

NX210

  Manage Alerts
Collapse Summary General Information
Company Neuronax S.A.S
DescriptionSynthetic peptide derived from subcommissural organ-spondin
Molecular Target
Mechanism of Action 
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPreclinical
Standard IndicationSpinal cord injury (SCI)
Indication DetailsTreat spinal cord injuries
Regulatory Designation EU - Orphan Drug (Treat spinal cord injuries)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today